All
10 December 2025
Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases
Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced the appointment of five globally...
8 December 2025
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
8 December 2025
First patient dosed in Citryll’s phase IIA Hidradenitis Suppurativa Trial
Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular Traps (ETs), today announces the...
2 December 2025
Enterome OncoMimics™ immunotherapy EO2401 shows survival benefit in Phase 2 glioblastoma trial
Enterome, a clinical-stage company pioneering OncoMimics™ peptides, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent...
14 November 2025
MaaT Pharma announces the successful completion of its Global Offering of €9.1 million
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
30 October 2025
Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $ 401M)
• New investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing join Series C syndicate led by Venrock Healthcare...
22 October 2025
Vertero Unveils New Strategic Direction Focused on Breaking Barriers in Neurodegenerative Diseases
Axial Therapeutics today announced that it has rebranded as Vertero Therapeutics, a biotechnology company breaking barriers in neurodegenerative disease treatment. The new...
16 October 2025
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Enterome, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces today that the U.S. Food and Drug Administration (FDA) has...
1 October 2025
Sunrise Group: $29 Million Raised For Expanding Dreem Health
Sunrise Group, known as a leader in sleep health technology, has announced a funding round of $29 million dedicated to expanding Dreem Health, its innovative digital sleep...